Three structurally independent platforms. One governing model: industry funds the work, Zentek owns the IP. Albany is the raw material foundation. Graphene and Triera are the revenue engines.
Each platform operates the same development-on-demand CRO model. Client funds the work. Zentek owns the IP. Government grants offset a meaningful portion of R&D cost.
Hydrothermal, igneous-hosted deposit in Northern Ontario. Demonstrated 99.9992% C purity and 2.60 ppm EBC through FBR purification. No allied-nation natural graphite source has demonstrated comparable specification.
Four product families. ZenGUARD™, GraphGel™, ZenICE™, ZenArmor™: addressing fire, ice, corrosion, and filtration challenges. Active US pilot with Quality Filters Inc.
Aptamer-based diagnostics and custom molecular discovery, built on a 20-year exclusive McMaster University IP license. 21,000+ published papers of foundational science. 100% ML classification accuracy on 172 real patient samples. CRO services now open.
Zentek is actively seeking strategic partners and long-term investors who recognise the convergence of critical minerals supply chain urgency, advanced material performance demand, and next-generation therapeutic development.
Coming soon · request via investor relations below
All public disclosures via ACCESS Newswire
Canadian regulatory filings · all continuous disclosure
ir@zentek.com
Strategic partnerships, licensing, and co-development